- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02164461
ADXS11-001 High Dose HPV+ Cervical Cancer
March 4, 2019 updated by: Advaxis, Inc.
PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX
To evaluate the tolerability and safety of ADXS11-001 (1 x 10^10 colony forming units [cfu]) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or recurrent squamous and non-squamous carcinoma, adenosquamous, or adenocarcinoma of the cervix.
To evaluate tumor response and progression-free survival (PFS, time to progression) by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States
- Recruiting
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Recruiting
-
-
New York
-
Bronx, New York, United States
- Recruiting
-
-
Virginia
-
Charlottesville, Virginia, United States
- Recruiting
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients with histologically-confirmed, persistent, metastatic or recurrent squamous or non-squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix with documented disease progression (disease not amenable to surgery or standard radiotherapy).
- Patients who have received no more than 1 prior cytotoxic treatment regimen.
- Subject may have received ≤2 prior regimens for the treatment of their metastatic disease.
- Subject is able to provide written informed consent.
- Subject must have an ECOG performance status of 0 or 1.
Exclusion Criteria:
- In the opinion of the investigator, subject has rapidly progressing disease, OR has life expectancy of less than 6 months, OR would be unable to receive at least one cycle of therapy.
- Subject has received chemotherapy and/or radiation therapy (except palliative radiation therapy for disease-related pain) within ≤2 weeks of first ADXS11-001 infusion.
- Subject has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Has a contraindication to administration of trimethoprim/sulfamethoxazole or ampicillin.
- Has implanted medical device(s) that pose a high risk for colonization and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous implant(s)). NOTE: More common devices and prosthetics which include arterial and venous stents, dental and breast implants, and venous access devices (e.g., Port-a-Cath or Mediport) are permitted. Sponsor must be contacted prior to consenting any subject who has any other device and/or implant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ADXS11-001
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with dose-limiting toxicities, as assessed by CTCAE v 4.0
Time Frame: 12 weeks
|
12 weeks
|
Frequency and severity of adverse effects as assessed by CTCAE v 4.0
Time Frame: Up to 3 years
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in clinical immunology based upon serum
Time Frame: Baseline to up to 24 hours after dose 3
|
Baseline to up to 24 hours after dose 3
|
Proportion of patients who have objective tumor response (complete or partial)
Time Frame: Up to 3 years
|
Up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
April 1, 2017
Study Completion (Actual)
July 1, 2018
Study Registration Dates
First Submitted
June 13, 2014
First Submitted That Met QC Criteria
June 13, 2014
First Posted (Estimate)
June 16, 2014
Study Record Updates
Last Update Posted (Actual)
March 5, 2019
Last Update Submitted That Met QC Criteria
March 4, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
- Carcinoma
- Neoplasms
- Adenocarcinoma
- Urogenital Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Neoplasms by Site
- Uterine Cervical Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Genital Diseases, Female
- Genital Neoplasms, Female
- Uterine Neoplasms
- Small Cell Lung Carcinoma
- Uterine Diseases
- Uterine Cervical Diseases
- Carcinoma, Small Cell
- Carcinoma, Adenosquamous
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Neoplasms, Complex and Mixed
- Uterine Cervical Neoplasms
- Carcinoma
- Adenocarcinoma
- Small Cell Lung Carcinoma
- Carcinoma, Adenosquamous
- Carcinoma, Small Cell
Other Study ID Numbers
- Lm-LLO-E7-1401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Effects of Immunotherapy
-
Shanghai Juncell TherapeuticsSir Run Run Shaw HospitalRecruitingAdvanced Solid Tumor | Treatment Side Effects | Effects of Immunotherapy | Tumor Infiltrating LymphocytesChina
-
Philippe BéginThe Hospital for Sick Children; Centre de recherche du Centre hospitalier universitaire... and other collaboratorsRecruitingImmunotherapy | Physiological Effects of Drugs | Food IgE-mediated Allergy | OmalizumabCanada
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingBreast Cancer | Advanced Breast Cancer | Treatment Side Effects | Effects of ImmunotherapyChina
-
Aalborg UniversityCompletedQuality of Life | Hypersensitivity | Asthma | Effects of Immunotherapy | Rhino-Conjunctivitis
-
RadiotherapieCompletedMelanoma | Effects of Immunotherapy | Adverse Effect of Radiation TherapyBelgium
-
Michael von WolffUniversity of BernNot yet recruitingCancer | Fertility Issues | Effects of Immunotherapy | Toxicity Due to Chemotherapy | Toxicity Due to Radiotherapy | Fertility Preservation
-
University Hospital, GrenobleInstitut National de la Santé Et de la Recherche Médicale, France; Etablissement... and other collaboratorsCompletedMelanoma | Effects of Immunotherapy | Tumor VaccinesFrance
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingTreatment Side Effects | Effects of Immunotherapy | Advanced Liver Cancers | Tumor Infiltrating Lymphocyte | Advanced Pancreatic CancersChina
-
Leiden UniversityBristol-Myers SquibbActive, not recruitingEffects of Immunotherapy | Adverse Drug Event | Toxicity, DrugNetherlands
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingTreatment Side Effects | Effects of Immunotherapy | Advanced Melanoma | Tumor Infiltrating LymphocyteChina
Clinical Trials on ADXS11-001
-
Andrew SikoraAdvaxis, Inc.CompletedHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | HPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Advaxis, Inc.CompletedRectal Cancer | Anal CancerUnited States
-
University of LiverpoolCancer Research UK; Liverpool University Hospitals NHS Foundation Trust; Advaxis... and other collaboratorsTerminatedHPV-16 +ve Oropharyngeal CarcinomaUnited Kingdom
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Advaxis, Inc.CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical CarcinomaUnited States
-
Advaxis, Inc.MedImmune LLCTerminatedCervical Cancer | Cancer | Head and Neck CancerUnited States
-
Advaxis, Inc.TerminatedCervical Intraepithelial NeoplasiaUnited States
-
Advaxis, Inc.Gynecologic Oncology GroupTerminatedHigh Risk Cervical Cancer | Advanced Cervical CancerUnited States, Argentina, Brazil, Canada, Chile, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Serbia, Spain, Taiwan, Ukraine
-
Second Affiliated Hospital, School of Medicine,...RecruitingCarotid Artery Plaque | Plaque, Atherosclerotic | Immune Checkpoint Inhibitors | Programmed Cell Death Protein 1 Inhibitor | Intimal Medial Thickness of Internal Carotid ArteryChina
-
Advaxis, Inc.Withdrawn
-
Brown UniversityThe Miriam Hospital; Rhode Island HospitalTerminatedAnal CancerUnited States